17966 Federal Register / Vol. 76, No. 62 / Thursday, March 31, 2011 / Notices 

reference to the applicable law and the 

evidentiary record. In connection with 

its review, the Commission is 

particularly interested in responses to 

the following questions: 

1. Kodak has argued in its petition for 

review that the ALJ made a ruling on 

obviousness with respect to prior art 

combinations that Kodak did not have 

an opportunity to address. The parties 

should address whether the ALJ 

permissibly relied on these prior art 

combinations and whether these 

combinations render claim 15 invalid 

for obviousness. 

2. Kodak has argued in its petition for 

review that the ALJ did not address the 

claim constructions of the presiding ALJ 

in Inv. No. 337–TA–663. The parties 

should address whether the ALJ should 

have considered the claim constructions 

in Inv. No. 337–TA–663 and what effect 

those constructions should have in this 

case. 

3. Kodak has argued in its petition for 

review that the ALJ did not address the 

reexaminations at the U.S. Patent and 

Trademark Office of the ’218 patent. The 

parties should address whether the ALJ 

should have considered the 

reexaminations and what effect those 

reexaminations should have in this case. 

4. Please explain whether U.S. Patent 

No. 5,493,335 is prior art, and if so, on 

what statutory basis. 

5. What is the meaning of ‘‘color pixel 

value’’ in part (b) of claim 15? Is it ‘‘the 

value of a color pixel’’? In your answer, 

address the patent’s discussion of each 

red, green, or blue element of a display 

being a ‘‘pixel’’ (column 8 lines 17–28). 

In connection with the final 

disposition of this investigation, the 

Commission may (1) issue an order that 

could result in the exclusion of the 

subject articles from entry into the 

United States, and/or (2) issue one or 

more cease and desist orders that could 

result in a respondent being required to 

cease and desist from engaging in unfair 

acts in the importation and sale of such 

articles. Accordingly, the Commission is 

interested in receiving written 

submissions that address the form of 

remedy, if any, that should be ordered. 

If a party seeks exclusion of an article 

from entry into the United States for 

purposes other than entry for 

consumption, the party should so 

indicate and provide information 

establishing that activities involving 

other types of entry either are adversely 

affecting it or likely to do so. For 

background, see In the Matter of Certain 

Devices for Connecting Computers via 

Telephone Lines, Inv. No. 337–TA–360, 

USITC Pub. No. 2843 (December 1994) 

(Commission Opinion). 

If the Commission contemplates some 

form of remedy, it must consider the 

effects of that remedy upon the public 

interest. The factors the Commission 

will consider include the effect that an 

exclusion order and/or cease and desist 

orders would have on (1) the public 

health and welfare, (2) competitive 

conditions in the U.S. economy, (3) U.S. 

production of articles that are like or 

directly competitive with those that are 

subject to investigation, and (4) U.S. 

consumers. The Commission is 

therefore interested in receiving written 

submissions that address the 

aforementioned public interest factors 

in the context of this investigation. 

If the Commission orders some form 

of remedy, the United States Trade 

Representative, as delegated by the 

President, has 60 days to approve or 

disapprove the Commission’s action. 

See Presidential Memorandum of July 

21, 2005, 70 FR 43251 (July 26, 2005). 

During this period, the subject articles 

would be entitled to enter the United 

States under bond, in an amount 

determined by the Commission and 

prescribed by the Secretary of the 

Treasury. The Commission is therefore 

interested in receiving submissions 

concerning the amount of the bond that 

should be imposed if a remedy is 

ordered. 

Written Submissions: The parties to 

the investigation are requested to file 

written submissions on the issues 

identified in this notice. Parties to the 

investigation, interested government 

agencies, and any other interested 

parties are encouraged to file written 

submissions on the issues of remedy, 

the public interest, and bonding. Such 

submissions should address the 

recommended determination by the ALJ 

on remedy and bonding. Complainant 

and the Commission investigative 

attorney are also requested to submit 

proposed remedial orders for the 

Commission’s consideration. 

Complainant is also requested to state 

the date that the patent expires and the 

HTSUS numbers under which the 

accused products are imported. The 

written submissions and proposed 

remedial orders must be filed no later 

than close of business on Friday April 

8, 2011. Reply submissions must be 

filed no later than the close of business 

on Friday April 15, 2011. The written 

submissions must be no longer than 100 

pages and the reply submissions must 

be no longer than 50 pages. No further 

submissions on these issues will be 

permitted unless otherwise ordered by 

the Commission. 

Persons filing written submissions 

must file the original document and 

12 true copies thereof on or before the 

deadlines stated above with the Office 

of the Secretary. Any person desiring to 

submit a document to the Commission 

in confidence must request confidential 

treatment unless the information has 

already been granted such treatment 

during the proceedings. All such 

requests should be directed to the 

Secretary of the Commission and must 

include a full statement of the reasons 

why the Commission should grant such 

treatment. See 19 CFR 210.6. Documents 

for which confidential treatment by the 

Commission is sought will be treated 

accordingly. All non-confidential 

written submissions will be available for 

public inspection at the Office of the 

Secretary. 

The authority for the Commission’s 

determination is contained in section 

337 of the Tariff Act of 1930, as 

amended (19 U.S.C. 1337), and in 

sections 210.42–46 and 210.50 of the 

Commission’s Rules of Practice and 

Procedure (19 CFR 210.42–46 and 

210.50). 

Issued: March 25, 2011. 

By order of the Commission. 

James R. Holbein, 

Acting Secretary to the Commission. 

[FR Doc. 2011–7553 Filed 3–30–11; 8:45 am] 

BILLING CODE P 

INTERNATIONAL TRADE 

COMMISSION 

[USITC SE–11–008] 

Government In the Sunshine Act 

Meeting Notice 

AGENCY HOLDING THE MEETING: United 

States International Trade Commission. 

TIME AND DATE: April 12, 2011 at 11 a.m. 

PLACE: Room 110, 500 E Street, SW., 

Washington, DC 20436. Telephone: 

(202) 205–2000. 

STATUS: Open to the public. 

MATTERS TO BE CONSIDERED: 

1. Agendas for future meetings: none. 

2. Minutes. 

3. Ratification List. 

4. Vote in Inv. Nos. 731–TA–1084– 

1087 (Review) (Purified 

Carboxymethylcellulose from Finland, 

Mexico, Netherlands, and Sweden). The 

Commission is currently scheduled to 

transmit its determinations and 

Commissioners’ opinions to the 

Secretary of Commerce on or before May 

3, 2011. 

5. Outstanding action jackets: none. 

In accordance with Commission 

policy, subject matter listed above, not 

disposed of at the scheduled meeting, 

may be carried over to the agenda of the 

following meeting. Earlier Notification 

of this meeting was not possible. 


wwoods2 on DSK1DXX6B1PROD with NOTICES
Federal Register / Vol. 76, No. 62 / Thursday, March 31, 2011 / Notices 17967 

By order of the Commission: 

Issued: March 28, 2011. 

William R. Bishop, 

Hearings and Meetings Coordinator. 

[FR Doc. 2011–7671 Filed 3–29–11; 11:15 am] 

BILLING CODE 7020–02–P 

JOINT BOARD FOR THE 

ENROLLMENT OF ACTUARIES 

Meeting of the Advisory Committee; 

Meeting 

AGENCY: Joint Board for the Enrollment 

of Actuaries. 

ACTION: Notice of Federal Advisory 

Committee meeting. 

SUMMARY: The Executive Director of the 

Joint Board for the Enrollment of 

Actuaries gives notice of a closed 

meeting of the Advisory Committee on 

Actuarial Examinations. 

DATES: The meeting will be held on 

April 29, 2011, from 8:30 a.m. to 5 p.m. 

ADDRESSES: The meeting will be held at 

Mercer, 4400 Comerica Bank Tower, 

1717 Main Street, Dallas, TX 75201. 

FOR FURTHER INFORMATION CONTACT: 

Patrick W. McDonough, Executive 

Director of the Joint Board for the 

Enrollment of Actuaries, 202–622–8225. 

SUPPLEMENTARY INFORMATION: Notice is 

hereby given that the Advisory 

Committee on Actuarial Examinations 

will meet at Mercer, 4400 Comerica 

Bank Tower, 1717 Main Street, Dallas, 

TX, on April 29, 2011, from 8:30 a.m. 

to 5 p.m. 

The purpose of the meeting is to 

discuss topics and questions that may 

be recommended for inclusion on future 

Joint Board examinations in actuarial 

mathematics, pension law and 

methodology referred to in 29 U.S.C. 

1242(a)(1)(B). 

A determination has been made as 

required by section 10(d) of the Federal 

Advisory Committee Act, 5 U.S.C. App., 

that the subject of the meeting falls 

within the exception to the open 

meeting requirement set forth in Title 5 

U.S.C. 552b(c)(9)(B), and that the public 

interest requires that such meeting be 

closed to public participation. 

Dated: March 25, 2011. 

Patrick W. McDonough, 

Executive Director, Joint Board for the 

Enrollment of Actuaries. 

[FR Doc. 2011–7518 Filed 3–30–11; 8:45 am] 

BILLING CODE 4830–01–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated October 8, 2010, and 

published in the Federal Register on 

October 20, 2010 75 FR 64744, Hospira 

Inc., 1776 North Centennial Drive, 

McPherson, Kansas 67460–1247, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of 

Remifentanil (9739), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to import 

Remifentanil for use in dosage form 

manufacturing. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a), 

and determined that the registration of 

Hospira Inc. to import the basic class of 

controlled substance is consistent with 

the public interest, and with United 

States obligations under international 

treaties, conventions, or protocols in 

effect on May 1, 1971, at this time. DEA 

has investigated Hospira Inc. to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed. 

Dated: March 21, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–7537 Filed 3–30–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated October 19, 2010, and 

published in the Federal Register on 

October 26, 2010, 75 FR 65658, Cody 

Laboratories Inc., 601 Yellowstone 

Avenue, Cody, Wyoming 82414–3921, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as an importer of 

the following basic classes of controlled 

substances: 

Drug Schedule 

Raw Opium (9600) ....................... II 

Concentrate of Poppy Straw 

(9670).

II 

The company plans to import narcotic 

raw materials for manufacturing and 

further distribution to its customers. 

The company is registered with DEA as 

a manufacturer of several controlled 

substances that are manufactured from 

raw opium, poppy straw, and 

concentrate of poppy straw. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Cody Laboratories, Inc. to import the 

basic classes of controlled substances is 

consistent with the public interest, and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971. DEA 

has investigated Cody Laboratories, Inc. 

to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: March 21, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–7542 Filed 3–30–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated November 19, 2010, 

and published in the Federal Register 

on December 3, 2010 75 FR 75494, 

Mylan Technologies, Inc., 110 Lake 

Street, Saint Albans, Vermont 05478, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as an importer of 

the following basic classes of controlled 

substances: 


wwoods2 on DSK1DXX6B1PROD with NOTICES